RVMD Latest Headlines

Bernstein Reaffirms Their Hold Rating on Revolution Medicines (RVMD)

at www.tipranks.com (Tue, 2-Jun 9:06 AM)

Analyst Reiterates Buy on Revolution Medicines Amid Strong ASCO Feedback and Optimism for RAS-Targeted Solid Tumor Portfolio

at www.tipranks.com (Tue, 2-Jun 8:56 AM)

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), IN8bio (INAB) and PolyPid (PYPD)

at www.tipranks.com (Mon, 1-Jun 11:10 AM)

Stifel Nicolaus Sticks to Their Buy Rating for Revolution Medicines (RVMD)

at www.tipranks.com (Mon, 1-Jun 8:45 AM)

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Crescent Biopharma (CBIO) and Erasca (ERAS)

at www.tipranks.com (Mon, 1-Jun 8:40 AM)

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Veeva Systems (VEEV)

at www.tipranks.com (Mon, 1-Jun 8:30 AM)

Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

at www.tipranks.com (Mon, 1-Jun 8:15 AM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Mon, 1-Jun 8:00 AM)

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

at www.tipranks.com (Mon, 1-Jun 7:59 AM)

Wells Fargo Sticks to Its Buy Rating for Revolution Medicines (RVMD)

at www.tipranks.com (Mon, 1-Jun 7:39 AM)

Ami Fadia Reiterates Buy on Strong Daraxonrasib Data, Maintains $183 Price Target

at www.tipranks.com (Mon, 1-Jun 7:35 AM)

At a glance: stocks gapping up premarket

at seekingalpha.com (Mon, 1-Jun 6:35 AM)

Revolution Medicines Raises $2 Billion Through Upsized Stock and Convertible Note Offerings—Key Details and Implications

Market Chameleon (Wed, 15-Apr 8:55 AM)

Revolution Medicines Unveils $1 Billion Capital Raise via Dual Offerings—What’s Next for Its RAS-Targeted Pipeline?

Market Chameleon (Tue, 14-Apr 11:45 AM)

Daraxonrasib’s Breakthrough in Pancreatic Cancer: Revolution Medicines’ Phase 3 Trial Shows Median Survival Doubled

Market Chameleon (Mon, 13-Apr 11:53 AM)

Daraxonrasib Delivers Unmatched Overall Survival in Metastatic Pancreatic Cancer: Pivotal Phase 3 Results Redefine Treatment Possibilities

Market Chameleon (Mon, 13-Apr 8:23 AM)